Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.

[1]  M. Ivan,et al.  Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection , 2020, Journal of Neuro-Oncology.

[2]  K. Aigner,et al.  Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series , 2020, Frontiers in Oncology.

[3]  Dexi Chen,et al.  Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma , 2020, Frontiers in Immunology.

[4]  E. Chiocca,et al.  Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual? , 2018, Neuro-oncology.

[5]  M. Westphal,et al.  Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes , 2018, Clinical Cancer Research.

[6]  K. Aldape,et al.  Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  N. Vitanza,et al.  Immunotherapy for brain tumors: understanding early successes and limitations , 2018, Expert review of neurotherapeutics.

[8]  M. Khasraw,et al.  Outcomes after second surgery for recurrent glioblastoma: a retrospective case–control study , 2018, Journal of Neuro-Oncology.

[9]  F. Lieberman,et al.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.

[10]  Martin Klein,et al.  Lomustine and Bevacizumab in Progressive Glioblastoma , 2017, The New England journal of medicine.

[11]  F. Sánchez‐Madrid,et al.  CD69: from activation marker to metabolic gatekeeper , 2017, European journal of immunology.

[12]  R. Moats,et al.  Human Neural Stem Cell Biodistribution and Predicted Tumor Coverage by a Diffusible Therapeutic in a Mouse Glioma Model , 2017, Stem cells translational medicine.

[13]  P. Frankel,et al.  Neural Stem Cell–Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients , 2016, Clinical Cancer Research.

[14]  Atique U. Ahmed,et al.  Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters , 2016, Journal of Translational Medicine.

[15]  Naoya Hashimoto,et al.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.

[16]  Troy Guthrie,et al.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R A Moats,et al.  Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction , 2014, Cancer Gene Therapy.

[18]  Jason B. Williams,et al.  Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.

[19]  Atique U. Ahmed,et al.  The Timing of Neural Stem Cell‐Based Virotherapy Is Critical for Optimal Therapeutic Efficacy When Applied With Radiation and Chemotherapy for the Treatment of Glioblastoma , 2013, Stem cells translational medicine.

[20]  Atique U. Ahmed,et al.  A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. , 2013, Journal of the National Cancer Institute.

[21]  Rex A. Moats,et al.  Neural Stem Cell–Mediated Enzyme/Prodrug Therapy for Glioma: Preclinical Studies , 2013, Science Translational Medicine.

[22]  Ziheng Zhang,et al.  Syndecan-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis , 2012, Molecular Biology Reports.

[23]  M. Nicholas,et al.  Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. , 2011, Seminars in oncology.

[24]  Elena Cattaneo,et al.  Neural stem cell systems: physiological players or in vitro entities? , 2010, Nature Reviews Neuroscience.

[25]  A. Sonabend,et al.  Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo , 2009, British Journal of Cancer.

[26]  A. Schönthal,et al.  Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. , 2008, The American journal of pathology.

[27]  L. Molinero,et al.  Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. , 2008, Cancer research.

[28]  A. Rivera,et al.  Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. , 2007, Human gene therapy.

[29]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[30]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[31]  J. Olson,et al.  A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  Susan M. Chang,et al.  Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. Black,et al.  Quantitatively determined survivin expression levels are of prognostic value in human gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. Black,et al.  Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Cella,et al.  The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT‐G) in patients with primary brain tumors , 1995, Cancer.

[36]  J. Fueyo,et al.  Targeting brain tumor stem cells with oncolytic adenoviruses. , 2012, Methods in molecular biology.